AJ Lanigan: Indeed. In Truth, pharma organizations are generating large dollars with treatment plans like Keytruda and Opdivo that deal with PD-1 and PD-L1. Here’s the super interesting element: think of checkpoints as targeted visitors alerts. You don’t want an immune technique that’s managing wild just like a freight prepare waiting for link from Social Bookmarking (2)